FLECT/CT Used to Investigate a Genetic Treatment for Cardiac Hypertrophy

  • FLECT/CT Used to Investigate a Genetic Treatment for Cardiac Hypertrophy

    A team of researchers from China have used the TriFoil InSyte FLECT/CT system in a study investigating a genetic treatment to reverse a decrease in the Dopamine D5 receptor (D5R) expression and treat cardiac hypertrophy, a precursor to heart failure. Their treatment regime utilises Drd5 nucleic acids delivered by a non-viral delivery vector (tobramycin-based hyperbranched polyaminoglycoside, or SS-HPT).

    More specifically, the InSyTe FLECT/CT was used to study the biodistribution of the SS HPT/NA complex used to deliver Drd5 nucleic acid treatment. They found that there was a twofold higher accumulation of the SS HPT/ NA complex in the heart of TAC mice compared to the control mice.

    The in vivo imaging results from the InSyTe FLECT/CT are significant as this enabled the research team to gain an understanding of the in vivo distribution of the novel genetic therapy in the internal organs of the mouse with high resolution and quantification.

    Their work was published in the journal, Advanced Science on 6 January, 2021. The full paper is available in the journal Advanced Science via open access.